about
Familial hypercholesterolemia: Review of diagnosis, screening, and treatmentThe art of planning.Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update.Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes.Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists.The importance of in-hospital statin therapy for patients with acute coronary syndromes.Professional use of social media by pharmacistsEvolution in the practice of pharmacy--not a revolution!A Change of Seasons-A New Beginning!An evaluation of teaching physical examination to pharmacists.New advances in antirejection therapy.Belonging to CSHP-An Investment in Your Future and That of Hospital Pharmacy!A randomized trial of a community-based approach to dyslipidemia management: Pharmacist prescribing to achieve cholesterol targets (RxACT Study)Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients--a systematic review.Colchicine for the primary and secondary prevention of pericarditis: an update.The Pursuit of Professional Practice Excellence and the Achievement of Peer Recognition.Frequency of intensive statin therapy in patients with acute coronary syndrome admitted to a tertiary care center.2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.Adverse drug reactions: The importance of maintaining pharmacovigilanceDiagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.A new year-time for reconciliation.Une nouvelle année : l'heure est au bilan.Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?2016 Guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists.Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus).Supratherapeutic response to ezetimibe administered with cyclosporine.Hypercholestérolémie familiale: Révision du diagnostic, du dépistage et du traitement.Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease.Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection.Prevention and management of statin adverse effects: A practical approach for pharmacists.Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 updateComment: Should an LDL Cholesterol Target–Based Approach Be Readopted?A review of the use of direct oral anticoagulant use in orthotopic heart transplantation recipientsQ59314538Q59314558Cardiovascular MRI Predicts 5-Year Adverse Clinical Outcome in Heart Transplant RecipientsQ59314570
P50
Q26770143-EBC2972A-5A7A-417C-96E5-F361BF522CE1Q34125537-CC0DB0A3-F778-4F46-AC12-A7196214D32FQ34387237-8FD960DF-339D-4CA6-9265-5B6DFB2C09D8Q34419187-FB8B0110-B4CC-4F00-9738-AA9E6707D406Q34522522-5125DDD2-C31B-4EA2-AD96-13309FC10CEEQ34961885-DF9AE4EC-70EB-4A21-8427-609370579654Q35101478-D5FD37A2-AB72-4591-8C85-E8C6B5FDA555Q35150120-776C71E4-4A01-4507-9F0F-CCDD61C34F8EQ35752948-C28AEDA9-8903-4482-85EE-606B9C5DE068Q36161234-DE7B92FA-690A-44F3-A89E-CEF9125E4912Q36596679-67D91C3E-EB39-4359-8C4B-97F0030935FCQ36729992-4067B219-26BD-4FB5-BCFC-886A67FDCA9BQ36858334-08135E47-9CE7-4FD6-86F8-9BECC6D87EB9Q37275370-E35914D0-99D2-426E-BFE5-F37A4EBB811CQ37432722-D0C10150-1C29-4974-86D3-0CECE417F83BQ37630832-A02399D1-B080-467E-A867-6FE739B381CAQ37711159-7DE2176C-5CBE-4449-90F7-25E1B752F5D0Q37943503-E0E0DE8C-1B9E-4FB8-8638-E07AD354276AQ38076875-837EBBD3-AF9C-4894-9EA8-D7D8876564FDQ38264124-23CFE318-1954-4BFC-9171-9BDAA574A7BDQ38876388-1543A9FC-1A51-4919-B1BF-6C637B855777Q38974082-32947537-9650-456A-A0C2-9374AE77CC40Q41761739-7C13601C-88B5-4153-8A75-8504C2150F66Q43177188-66209888-CA10-45FC-8193-0C66A902A5D5Q43506365-5158BF6A-5760-4E94-899B-2F9BD46CFE7EQ44545208-BA34C149-9420-4078-B5E6-06F21D766E38Q46058517-6BB86803-A365-434B-AC2C-30C5B2F64C30Q46378376-412E5FD0-B0B4-4501-92F3-3F08B06B4E1EQ46609143-9E6EF34A-E773-4C06-9E71-E1231C6AD1D0Q46840217-8F80EE9F-1F5A-4E80-8911-F1C84D4D59A2Q48507918-D2AE76DB-FC99-44E7-BE33-9B1A81C9A3A0Q53247343-1DB1EDF0-EB00-4D62-8BA5-0CB3C2AC44A8Q55154739-4269C555-A874-4FEC-894E-784C17B1C86AQ57288263-402861F4-662C-4192-B8D5-17FD501578CAQ59314527-D9C39399-9BC1-40C6-8B23-1BB55F0C2BD9Q59314528-69097EC7-A148-4061-8C00-029FF74C5788Q59314538-7004BBF0-CFA4-4552-B639-3A3929F9940EQ59314558-FE5669B6-4A2E-4963-9DC3-BEDBA2E9E4FEQ59314562-DA22C380-FA7B-4D20-AAC6-37FF2BD0FF6FQ59314570-CA23EA95-326E-41FC-BCA6-6858044CB384
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Glen J Pearson
@ast
Glen J Pearson
@en
Glen J Pearson
@es
Glen J Pearson
@nl
type
label
Glen J Pearson
@ast
Glen J Pearson
@en
Glen J Pearson
@es
Glen J Pearson
@nl
prefLabel
Glen J Pearson
@ast
Glen J Pearson
@en
Glen J Pearson
@es
Glen J Pearson
@nl
P106
P1153
7201899194
P31
P496
0000-0003-3281-7915